



Nigeria

Support for Vaccine: Meningococcal type A

This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Nigeria																					
2. Vaccine grant number:	NGA-MENA-R, NGA-MENA-R-VAC, NGA-MENA-R-VIG, NGA-MENA-R-VIG-UNIC, NGA-MENA-R-VIG-WHO																					
3. Date of Decision Letter:	29 November, 2019																					
4. Date of the Partnership Framework Agreement:	9 January, 2014																					
5. Programme title:	New Vaccine Support (NVS), Meningococcal type A, Routine																					
6. Vaccine type:	Meningococcal type A																					
7. Requested product presentation and formulation of vaccine:	Meningococcal type A, 10 dose(s) per vial, LYOPHILISED																					
8. Programme Duration:¹	2019-2020																					
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
	2019	2020	2021	2022	2023	2024	Total ²															
Programme Budget (US\$)	6,257,724	1,776,500	-	-	-	-	8,034,224															
10. Vaccine introduction grant																						
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2019</td> <td style="text-align: center;">NGA-MENA-R-VIG</td> <td style="text-align: right;">2,202</td> </tr> <tr> <td style="text-align: center;">2019</td> <td style="text-align: center;">NGA-MENA-R-VIG-UNIC</td> <td style="text-align: right;">1,228,515</td> </tr> <tr> <td style="text-align: center;">2019</td> <td style="text-align: center;">NGA-MENA-R-VIG-WHO</td> <td style="text-align: right;">3,835,699</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2019	NGA-MENA-R-VIG	2,202	2019	NGA-MENA-R-VIG-UNIC	1,228,515	2019	NGA-MENA-R-VIG-WHO	3,835,699
Approval																						
Year	Grant Number	Amount (US\$)																				
2019	NGA-MENA-R-VIG	2,202																				
2019	NGA-MENA-R-VIG-UNIC	1,228,515																				
2019	NGA-MENA-R-VIG-WHO	3,835,699																				
11. Product switch grant	Not applicable																					
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)																					
Type of supplies to be purchased with Gavi funds	2019	2020					2021															
Number of vaccine doses		2,943,000					-															

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Number of AD syringes		2,266,500	
Number of re-constitution syringes		323,800	
Number of safety boxes		28,500	
Annual Amounts (US\$)	6,257,716	1,776,500	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:
According to the co-financing policy, the Country falls within the group: Accelerated transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	731,000	-	-	-	-
Number of AD syringes	562,600	-	-	-	-
Number of re-constitution syringes	80,400	-	-	-	-
Number of safety boxes	7,075	-	-	-	-
Value of vaccine doses (US\$)	395,972	-	-	-	-
Total co-financing payments (US\$) (including freight)	440,879	-	-	-	-

16. Operational support for campaigns:
Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	31 March 15 May



<ul style="list-style-type: none"> Countries shall report the actual switch date in the first renewal request following the actual implementation. 	
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>
<p>18. Financial clarifications: Country shall provide the following clarifications to Gavi*:</p> <p>Not applicable</p> <p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>	
<p>19. Other conditions:</p> <p>Not applicable</p>	

Signed by,
Signed by,

On behalf of Gavi

Thabani Maphosa
Managing Director, Country Programmes
29/11/2019

